^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    COMPANY:
    RareCyte

    i
    Other names: RareCyte | RareCyte, Inc. | RareCyte Inc | RareCyte Inc. | RareCyte, Inc.
    Related tests:
    Evidence

    News

    almost2years
    RareCyte announces new Synaptophysin CTC assay for blood-based characterization of treatment-resistant malignancies (RareCyte Press Release)
    "RareCyte announces a new biomarker liquid biopsy assay for the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients. The Synaptophysin Panel Kit was validated to meet clinical standards and enables blood-based investigation of a prominent mechanism by which tumors become resistant to second-line endocrine therapies."
    Clinical
    over2years
    RareCyte announces first commercially available ARv7/Synaptophysin CTC assay for blood-based characterization of treatment resistant prostate cancer ()
    "RareCyte® announces a new dual biomarker liquid biopsy assay for androgen receptor splice variant 7 (ARv7) and the neuroendocrine marker, synaptophysin (SYP), enabling customers to evaluate both ARv7 and SYP expression on circulating tumor cells (CTCs) with industry leading accuracy and precision in patients with prostate cancer. The ARv7/Synaptophysin Panel Kit was validated based on rigorous requirements set to clinical standards and enables blood-based investigation of two prominent mechanisms by which tumors become resistant to second-line endocrine therapies."
    Commercial
    |
    RarePlex® ARv7/Synaptophysin CTC Panel Kit